The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

Slides:

Advertisements

Similar presentations

by Norman Nausch, Ioanna E

Advertisements

Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression by Rosalba Salcedo, Maria Lourdes.

Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.

by Cunren Liu, Shaohua Yu, John Kappes, Jianhua Wang, William E

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

CD1dhiCD5+ B cells are expanded in pancreatic neoplasia and are functionally important for sustaining growth of KrasG12D-PDEC in vivo. CD1dhiCD5+ B cells.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Volume 21, Issue 10, Pages (December 2017)

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

Estrogen drives accumulation of myelomonocytic (M-MDSC) and granulocytic (G-MDSC) MDSCs and increases the immunosuppressive potential of G-MDSCs. Estrogen.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Genetic FIP200 deletion impairs autophagy induction and causes T cell apoptosis. Genetic FIP200 deletion impairs autophagy induction and causes T cell.

Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells. Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Expression of p110γ isoform in macrophages promotes tumor growth and angiogenesis. Expression of p110γ isoform in macrophages promotes tumor growth and.

PTX in combination with PLX397 induces antitumor T-cell response.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

coTCRcys-transduced T cells control tumor growth in vivo.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

IDO deficiency delays the development of pulmonary metastases.

5FU-induced specific activation of CD8+ T cells.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Neutralization of CSF1 and Ad5-HRG treatment.

TILs upregulate CD137 in an HIF-1α–dependent fashion.

GM-CSF is required for CA-MSC–induced tumor metastasis.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

HMQ1611 inhibited breast tumor growth in mice.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

SPARC is required for spontaneous metastasis

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

T cells with a ROR1-specific CAR eliminate tumor cells in vivo only with a modified long spacer. T cells with a ROR1-specific CAR eliminate tumor cells.

Impact of IFNγ in B16 melanoma metastasis.

PDL192 and inhibit the growth of xenograft tumors.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

BV6 increases bone metastasis.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid cells. In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid.

In vivo shRNA screening strategy.

CD8+ depletion and IFN-γ–deficient myeloid cells and lung metastasis inhibition in Tgfbr2MyeKO mice. CD8+ depletion and IFN-γ–deficient myeloid cells and.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

CD38 regulates tumor growth and metastasis by adenosine-mediated CD8+ T-cell suppression. CD38 regulates tumor growth and metastasis by adenosine-mediated.

Presentation transcript:

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. A, quantification of the tumor burden in the lungs 10 days following intravenous tumor cell injection in animals treated with anti-CD8 anti-body or immunoglobulin G (IgG) control (n = 5/group). B, representative flow-cytometric analysis (left) and graph (right) depicting tumor cell apoptosis 24 hours following coculture of PyMT-MSP tumor cells and CD8+ T cells isolated from the blood of tumor-bearing WT and Ron TK−/− hosts (n = 3/group) and naïve hosts (n = 3/group). C, schematic of the experimental strategy to determine whether tumor-educated CD8+ T cells from Ron TK−/− mice were sufficient to inhibit metastatic lung colonization. D, quantification of the metastatic tumor burden in mice 10 days following intravenous injection of tumor cells (11 days following T-cell adoptive transfer; n = 4 for adoptive transfer of CD8+ T cells from WT or Ron TK−/− mice, and n = 10 for controls receiving no T cells). Data are depicted as mean ± SEM. *, P < 0.05; **, P < 0.005 (unpaired, two-sided t test). N.S., not statistically significant. Henok Eyob et al. Cancer Discovery 2013;3:751-760 ©2013 by American Association for Cancer Research